Tables 1.
Patient characteristics at baseline (n=67)
| Median | Range | |
| Age (years) | 64 | 19–84 |
| Woman (%) | 41 (61) | |
| Hemoglobin (g/dL) | 9.3 | 6.2 – 11.1 |
| White blood cells, ×109 L | 5.5 | 0.7–69.8 |
| Platelets, ×109/L | 43 | 9 –184 |
| Bone marrow blasts (%) | 62 | 12–92 |
| Number of patients | (%) | |
| Cytogenetic risk | ||
| Intermediate | 57 | 85 |
| Adverse | 3 | 4.5 |
| Insufficient analysis | 7 | 10.5 |
| Treatment | ||
| Intensive | 27 | 40 |
| Intensive+ven | 8 | 12 |
| HMA+ven | 18 | 27 |
| HMA+other | 3 | 4.5 |
| Low-dose cytarabine+other | 3 | 4.5 |
| Ven+ cladribine and low dose AraC | 8 | 12 |
| Allogeneic stem cell transplant | 32 | 48 |
| Best Response | ||
| CR | 60 | 89.5 |
| CRi | 7 | 10.5 |
Abbreviations: HMA: hypomethylating agent; ven:venetoclax